A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease
To determine the antitumor activity, based on the confirmed objective response rate, of
KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with
non-small cell lung cancer (NSCLC) whose disease has progressed following initial
chemotherapy for advanced or metastatic disease.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration